Skip to main content Skip to section navigation Skip to footer
Immunovant, Inc.
  • Home
  • About Us
  • Pipeline
    • Mechanism of Action
    • Indications
  • For Investors
    • Overview
    • Immunovant R&D Day
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Analyst Coverage
    • Governance
  • Join Us
    • Our Benefits
    • Our Careers
  • Contact Us

Presentations

For Investors

For Investors

  • Overview
  • Immunovant R&D Day
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Company Info

  • Overview
  • Management Team
  • Presentations
  • Contacts
  • FAQ
Jan 9, 2023

Corporate Presentation

Jun 8, 2022

Investor Presentation June 8, 2022

Jan 10, 2022

Phase 3 Development for Batoclimab in Myasthenia Gravis

rss_feed RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Immunovant, Inc. All Rights Reserved.
Privacy Policy Terms of Use Disclaimer Sitemap Manage Cookie Preferences